The company's pipeline includes zilovertamab (ROR1-targeting monoclonal antibody), ONCT-216 (ETS-family transcription factor inhibitor), ONCT-808 (ROR1-targeting CAR-T), and ONCT-534 (dual-action androgen receptor inhibitor). In July 2025, Oncternal sold its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics for a $3.0 million upfront payment, reflecting a shift to earlier-stage development programs.
Cyborg Score Rationale
Stock trading at $0.53 as of April 2026 reflects severe capital constraints typical of late-stage clinical biotech. Asset divestitures and minimal employee base (12 employees) suggest liquidity pressures. Lack of recent clinical progress updates or funding announcements compounds execution risk.
Top Insights
Divested lead ROR1 programs (zilovertamab, ONCT-808) to Ho'ola Therapeutics in July 2025 for $3.0M upfront, indicating prioritization of remaining ONCT-216 and ONCT-534 candidates
Minimal staff of 12 employees suggests heavily outsourced R&D or dormant operations
Stock price at $0.53 (April 2026) reflects severe share dilution and market skepticism
Founded 2013, headquartered in San Diego with 13-year track record of early-stage oncology drug development
Named Competitors
ROR1-targeted therapies — Immuno-oncology platform targeting ROR1 and other oncology targets